Pharmacodynamics of tubulin and tubulin-binding agents: Extending their potential beyond taxanes

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 2, 2008, Pages

  Andreopoulou, Eleni ^a   Muggia, Franco ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epothilones; Ixabepilone; Microtubules; Targeted therapy

Indexed keywords

21 AMINOEPOTHILONE B; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; COLCHICINE; DISCODERMOLIDE; DOCETAXEL; DOLASTATIN; DOXORUBICIN; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; ERIBULIN; ESTRAMUSTINE; HALICHONDRIN B; IXABEPILONE; LAULIMALIDE; N ACETYLCOLCHINOL PHOSPHATE; NAVELBINE; PACLITAXEL; SAGOPILONE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; TUBULIN; UNINDEXED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; CYTOTOXIN; EPOTHILONE DERIVATIVE; TUBULIN MODULATOR;

ADJUVANT THERAPY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEOPLASM; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PELVIS PAIN SYNDROME; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHARMACODYNAMICS; PROGNOSIS; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UTERINE TUBE CARCINOMA; VOMITING; BREAST TUMOR; FEMALE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOTOXINS; EPOTHILONES; FEMALE; HUMANS; TUBULIN MODULATORS;

EID: 52449134327     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.s.001     Document Type: Article

References (79)

1. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56:816-25.
2. Yamaguchi H, Paranawithana SR, Lee M W, et al. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002; 62:466-71.
3. Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol 2006; 33:421-35.
4. Gottesman MM, Pastan I, Ambudkar S V. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6:610-7.
5. Dumontet C, Sikic BI. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17:1061-70.
6. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-8.
7. Gerth K, Bedorf N, Höfle G, et al. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49:560-3.
8. Goodin S, Kane M P, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 2004; 22:2015-025.
9. Bollag DM, McQueney PA, Zhu J. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 1995; 55:2325-33.
10. Lee FYF, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-37.
11. Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 2007; 7:543-9.
12. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007; 12:271-80.
13. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol® ). J Biol Chem 1997; 272:2534-41.
14. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003; 63:6026-31.
15. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 2004: 305:866-9.
16. Chou T-C, Zhang X-G, Balog A. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A 1998; 95:9642-7.
17. Lee FY, Vite G, Hofle G. The discovery of BMS-310705: a water-soluble and chemically stable semisynthetic epothilone possessing potent parenteral and oral antitumor activity against models of taxane-sensitive and -resistant human tumors in vivo. Proc Am Assoc Cancer Res 2002; 43:792 (Abstract 3928).
18. Wartmann M, Altmann K. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2:123-48.
19. Giannakakou P, Sackett DL, Kang Y-K. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-25.
20. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10:1289-98.
21. Spriggs D, Soignet S, Bienvenu B, et al. Phase I first in-man study of the epothilone B analog BMS-247550 in patients with advanced cancer. Proc Am Soc Clin Oncol 2001; 20:108a (Abstract 2001).
22. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25:3421-7.
23. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-34.
24. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer. J Clin Oncol 2007; 25:3399-406.
25. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25:3415-20.
26. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407-14.
27. Hamel E, Sackett DL, Vourloumis D, et al. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999; 38:5490-8.
28. Mooberry SL, Tien G, Hernandez AH, et al. Laulimalide and isolau-limalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999; 59:653-60.
29. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000; 97:2904-9.
30. He L, Jagtap PG, Kingston DGI, et al. A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry 2000; 39:3972-8.
31. Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A 1999; 96:4256-61.
32. Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. J Biol Chem 1990; 39:1941-9.
33. Hammond LA, Ruvuna F, Cunningham CC, et al. Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2004; 23:212 (Abstract 3068).
34. Bai RL, Paull KD, Herald CL, et al. Halichondrin B and homohali-chondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991; 266:15882-9.
35. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4:1086-95.
36. Chang AY, Garrow GC. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 1995; 22(2 suppl 5):66-70; discussion 70-1.
37. Dittrich C, Zifko U, Fazeny B, et al. Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity? Ann Oncol 1994; 5:473-4.
38. Muggia FM, Keren-Rosenberg S, Koda R, et al. Estramustine phosphate and paclitaxel: a phase I study In women with breast and gynecological cancer. Breast Cancer Res Treat 1995; 37(suppl):89.
39. Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1996; 88:1079-80.
40. Kourousis C, Kakolyris S, Androulakis N, et al. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol 1998; 21:226-32.
41. Fumoleau P, Féty R, Delecroix V, et al. Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology (Williston Park) 1997; 11(6 suppl 6):29-31.
42. Campone M, Fumoleau P, Delecroix V, et al. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann Oncol 2001; 12:909-18.
43. Sewak S, Chachoua A, Hamilton A, et al. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. Anticancer Drugs 2003; 14:67-72.
44. Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003; 14:1518-24.
45. Wojtowicz M, Rothermel JD, Anderson J, et al. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer. Proc Am Soc Clin Oncol 2004; 23:411 (Abstract 4623).
46. Garcia AA, Keren-Rosenberg S, Parimoo D, et al. Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors. J Clin Oncol 1998; 16:2959-63.
47. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23:1439-46.
48. Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks Taxol binding and results in mitotic arrest. Chem Biol 1996; 3:287-93.
49. Honore S, Kamath K, Braguer D, et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 2004; 64:4957-64.
50. Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000; 6:1978-87.
51. Thomas E, Bunnell CA, Vahdat LT, et al. A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Breast Cancer Res Treat 2003; 82(suppl 1):s83 (Abstract 350).
52. Novel epothilone plus capecitabine versus capecitabine alone in patients with advanced breast cancer. ClinicalTrials.gov [Web site]. Available at: http://www.clinicaltrials.gov/ct/show/NCT00080301. Accessed: April 1, 2007.
53. Epothilone (ixabepilone) plus capecitabine versus capecitabine alone in patients with advanced breast cancer. ClinicalTrials. gov [Web site]. Available at: http://www.clinical trials.gov.ct/show/ NCT00082433. Accessed: April 1, 2007.
54. Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol 2007; 25(18 suppl):33s (Abstract 1006).
55. Ixabepilone and liposomal doxorubicin in treating patients with advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer or metastatic breast cancer. ClinicalTrials.gov [Web site]. Available at: http://www. clinicaltrials.gov/ct/show/NCT00182767. Accessed: April 1, 2007.
56. Perez EA, Hillman D W, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88:124-31.
57. Perez EA, Suman VJ, Fitch TR, et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology 2005; 69:117-21.
58. Lee FY, Castaneda S, Inigo I, et al. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 2005; 23(16 suppl):19s (Abstract 561).
59. Trastuzumab, ixabepilone and carboplatin in treating patients with HER2/neu-positive metastatic breast cancer. ClinicalTrials.gov [Web site]. Available at: http://www.clinicaltrials.gov/ct/gui/show/ NCT00077376. Accessed: April 1, 2007.
60. Trastuzumab and ixabepilone in treating women with HER2-positive metastatic breast cancer. ClinicalTrials.gov [Web site]. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00079326. Accessed: April 1, 2007.
61. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381-95.
62. VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 2004; 3:1605-13.
63. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-22.
64. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99:2060-9.
65. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10:415-27.
66. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drugs 2004; 13:1171-82.
67. Nihei Y, Suzuki M, Okano A, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999; 90:1387-95.
68. Hill SA, Lonergan SJ, Denekamp J, et al. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29A:1320-4.
69. Baguley BC, Holdaway KM, Thomsen LL, et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27:482-7.
70. Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57:1829-34.
71. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vasculartargeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-53.
72. Stevenson J P, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-38.
73. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004; 10:96-100.
74. Barlow SB, Gonzalez-Garay ML, Cabral F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J Cell Sci 2002; 115(pt 17):3469-78.
75. Llombart Cussac J, Baselga G, Manikhas E, et al. Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): preliminary efficacy and safety data. J Clin Oncol 2005; 23(16 suppl):25s (Abstract 586).
76. Lee H, Xu L, Wu S, et al. Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. J Clin Oncol 2006; 24(18 suppl):123s (Abstract 3011).
77. Wu S, Chasalow S, Lee H, et al. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. J Clin Oncol 2007; 25(18 suppl):103s (Abstract 2525).
78. McDaid HM, Mani S, Shen H-J, et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002; 8:2035-43.
79. Mani S, McDaid HM, Grossman A, et al. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol 2007; 18:190-5.